OncoMatch

OncoMatch/Clinical Trials/NCT03093688

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

Is NCT03093688 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Infusion of iNKT cells and CD8+T cells for non-small cell lung cancer.

Phase 1/2RecruitingShanghai Public Health Clinical CenterNCT03093688Data as of May 2026

Treatment: Infusion of iNKT cells and CD8+T cellsInvariant Natural killer T (iNKT) cells are a unique subset of lymphocytes that express homogeneous TCR recognizing KRN7000 which was up-regulated by many kinds of cancer cells. PD-1+CD8+T cells of patients with advanced tumor are most likely tumor-specified. Our hypothesis is that immunotherapy strategy of infusion of iNKT cells and PD-1+CD8+T cells may decrease the tumor burden and improve overall survival. The purpose of this study is to assess the safety and efficacy of treatment of patients with advanced solid tumor by infusing of iNKT cells and PD-1+CD8+T cells.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Small Cell Lung Cancer

Pancreatic Cancer

Hepatocellular Carcinoma

Gastric Cancer

Renal Cell Carcinoma

Lab requirements

Blood counts

Hemoglobin ≥8.0 g/dL, Neutrophils count ≥1E9/L, Lymphocytes count ≥ lower limit of institutional normal, Platelet count ≥50E9/L

Kidney function

Serum creatinine ≤2.0 mg/dL

Liver function

Serum bilirubin ≤2 x upper limit of institutional normal, AST/ALT ≤2 x upper limit of institutional normal

Laboratory values within the following ranges prior to receiving treatment of study agent: Hemoglobin≧8.0 g/dL, Neutrophils count≧1E9/L, Lymphocytes count≧lower limit of institutional normal, Platelet count≧50E9/L, Serum creatinine≦2.0 mg/dL, Serum bilirubin≦2 x upper limit of institutional normal, AST/ALT≦2 x upper limit of institutional normal

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify